Genelux Corp

NASDAQ:GNLXUnited States

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Contact Information

Headquarters

2625 Townsgate Road, Suite 230WESTLAKE VILLAGE, CA, United States 91361

Phone

805-267-9889

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Thomas Zindrick

Chief Financial Officer

Lourie Zak

Senior Vice President - Clinical Development

Tony Yu

Chief Technical Officer

Joseph Cappello

General Counsel, Corporate Secretary

Sean Ryder